Caplin Point Q1FY27: PAT +18.8% YoY to ₹179 Cr, EBITDA margin expands, tax caps NPM

Caplin Point's consolidated Q1 FY27 revenue from operations came in at ₹610.4 Cr, up 19.6% YoY (₹510.2 Cr) and 1.7% QoQ; total revenue (including other income) was ₹643.9 Cr, +20.7% YoY. Consolidated PAT (net profit for the period, before minority interest) was ₹179.1 Cr, up 18.8% YoY and 3.6% QoQ, with basic EPS of ₹23.27 versus ₹20.10 a year ago. Neither the current nor the year-ago quarter carries any exceptional item, so this is a clean, comparable growth number. Management issued no formal quantitative guidance ahead of this print, so there is no company target to grade against; the closest available yardstick is broad analyst consensus (not quarter-specific) pegging FY27 PAT growth at 15-20% — the 18.8% YoY print sits within that band. The operating story was actually stronger than the PAT growth alone suggests: EBITDA rose 23.0% YoY to ₹247.0 Cr with the EBITDA margin expanding to 38.4% from 37.7%, and PBT/EBIT margin rose to 35.0% from 34.6%. But gross margin slipped to 59.8% from 61.7% YoY as purchased/traded goods took a larger share of the cost mix, and the effective tax rate jumped to 20.5% (₹46.1 Cr tax on ₹225.2 Cr PBT) from 18.3% a year ago, compounded by a 32.8% YoY rise in depreciation as new capacity comes online. Net effect: consolidated PAT margin actually compressed to 27.8% from 28.3% YoY even as operating profitability improved — the quarter's real story is healthy operating leverage being partly offset below the line by tax and D&A, not a demand or pricing issue. US revenue was the standout at ₹137 Cr (per the press release), +26% YoY, now roughly 22% of the geographic mix versus 78% for Emerging Markets; by segment, Rest-of-World PBT grew to ₹158.4 Cr (Q1FY26: ₹151.5 Cr) while the USA segment's PBT nearly tripled YoY to ₹33.3 Cr (from ₹9.9 Cr) — the regulated-market business is scaling faster than its still-smaller revenue base, backed by Caplin Steriles' 60 approved ANDAs (40+ more filing/in development) and CSU's own-label US business (33 launches to date, ~90% market-share retention on launched products). Alongside results, the board recommended a ₹4/share (200%) final dividend on top of the ₹4 interim already paid in June, taking total FY26 dividend to ₹8/share, and approved Dr. Sridhar Ganesan's MD reappointment (two more years from Aug 25, 2026) plus D. Muralidharan's elevation to Whole-Time Director while he retains the CFO role. Chairman C.C. Paarthipan's press-release commentary framed the quarter as delivering "healthy growth across both Emerging Markets and the US" with "disciplined execution" — the revenue and EBITDA numbers support that framing, though management's commentary does not address the tax-rate increase that capped net profit growth. Free cash reserves stood at ₹1,502 Cr and total liquid assets at ₹2,875 Cr as of June 30, 2026, funding a ~₹1,000+ Cr capex program (roughly half nearing completion) entirely from internal accruals — the Pondicherry OSD/Dermatology expansion and the Gummidipoondi COL injectable facility are both targeted for Q1 FY28, and the Thervoy oncology API facility for Q4 FY27. With no formal guidance on record, the checkpoints going into Q2 are whether the effective tax rate normalizes, whether gross margin recovers off the traded-goods mix shift, and whether the 12 planned US launches and the first Pre-Filled Syringe filing materialize within FY27 as management indicated.